- Home
- SYBT vs APGE Comparison
SYBT vs APGE Comparison
Compare SYBT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- APGE
- Stock Information
- Founded
- SYBT 1904
- APGE 2022
- Country
- SYBT United States
- APGE United States
- Employees
- SYBT N/A
- APGE N/A
- Industry
- SYBT Major Banks
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYBT Finance
- APGE Health Care
- Exchange
- SYBT Nasdaq
- APGE Nasdaq
- Market Cap
- SYBT 2.1B
- APGE 2.4B
- IPO Year
- SYBT N/A
- APGE 2023
- Fundamental
- Price
- SYBT $66.45
- APGE $55.35
- Analyst Decision
- SYBT Hold
- APGE Strong Buy
- Analyst Count
- SYBT 3
- APGE 8
- Target Price
- SYBT $83.67
- APGE $94.63
- AVG Volume (30 Days)
- SYBT 111.2K
- APGE 923.1K
- Earning Date
- SYBT 10-29-2025
- APGE 11-12-2025
- Dividend Yield
- SYBT 1.93%
- APGE N/A
- EPS Growth
- SYBT 26.14
- APGE N/A
- EPS
- SYBT 4.58
- APGE N/A
- Revenue
- SYBT $378,633,000.00
- APGE N/A
- Revenue This Year
- SYBT $16.82
- APGE N/A
- Revenue Next Year
- SYBT $5.11
- APGE N/A
- P/E Ratio
- SYBT $14.50
- APGE N/A
- Revenue Growth
- SYBT 14.11
- APGE N/A
- 52 Week Low
- SYBT $60.75
- APGE $26.20
- 52 Week High
- SYBT $83.83
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- SYBT 40.65
- APGE 66.05
- Support Level
- SYBT $65.69
- APGE $54.80
- Resistance Level
- SYBT $68.84
- APGE $57.23
- Average True Range (ATR)
- SYBT 2.04
- APGE 2.61
- MACD
- SYBT 0.16
- APGE -0.18
- Stochastic Oscillator
- SYBT 28.64
- APGE 62.75
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.